Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.

International journal of pharmaceutics - 30 Jun 2010

Xiao Wenjing, Chen Xiang, Yang Li, Mao Yongqiu, Wei Yuquan, Chen Lijuan

Abstract excerpt

In our previous study, we developed a novel cationic liposome, which was modified with truncated human basic fibroblast growth factor (tbFGF) peptide. This tbFGF-mediated cationic liposome could deliver chemotherapeutic agents or gene specifically to FGFRs on tumors and obtained higher transfection efficiency than plain cationic liposomes. In order to investigate whether this novel cationic liposome could achieve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Chemistry, Pharmaceutical

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fibroblast Growth Factor 2

Share to Inhibitor of Apoptosis Proteins

Share to Inhibitory Concentration 50

Share to Liposomes

Share to Receptors, Fibroblast Growth Factor

Share to Survivin

Source

Identifiers

PMID: 20416367
DOI: 10.1016/j.ijpharm.2010.04.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.PMID 20416367Read ↗

Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.Semantic proximity Read ↗

Transferrin-Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer XenograftsSemantic proximity Read ↗

Dual-targeted cationic liposomes modified with hyaluronic acid and folic acid deliver siRNA Bcl-2 in the treatment of cervical cancerSemantic proximity Read ↗

Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.Semantic proximity Read ↗

Nuclear-Targeted TAT-PZLL-D3 Co-Delivery DOX and p53 for Chemotherapy Resistance of SCLCSemantic proximity Read ↗

Inhibition of lymphatic metastases by a survivin dominant-negative mutant.Semantic proximity Read ↗

Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.Semantic proximity Read ↗

Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive IntroductionSemantic proximity Read ↗

lnterferon‐β gene therapy for cancer: Basic research to clinical applicationSemantic proximity Read ↗

Intelligent TAT-coupled anti-HER2 immunoliposomes knock downed MDR1 to produce chemosensitize phenotype of multidrug resistant carcinoma.Semantic proximity Read ↗

p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome.Semantic proximity Read ↗

Synergistic effects of negative-charged nanoparticles assisted by ultrasound on the reversal multidrug resistance phenotype in breast cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.